Citius Oncology Inc. reported its financial results for the quarter ended December 31, 2025. The company recorded a net loss of USD 5.53 million for the period, compared to a net loss of USD 6.66 million in the same quarter of the previous year, reflecting a decrease of 17 percent. Revenue commenced in December 2025 following the commercial launch of LYMPHIR (E7777), an approved oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, contributing to a gross profit of USD 3.15 million for the quarter. As of December 31, 2025, Citius Oncology had an accumulated deficit of USD 69.57 million. The company noted that it has historically relied on funding from Citius Pharma and recently completed equity offerings, projecting that it and Citius Pharma collectively will have sufficient funds to continue operations through May 2026. Citius Oncology has retained Jefferies LLC as its exclusive financial advisor to evaluate strategic alternatives to maximize shareholder value. The company plans to seek additional capital through future equity financings and to generate further revenue from LYMPHIR sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-015877), on February 13, 2026, and is solely responsible for the information contained therein.